VEGFR Inhibitor Tivozanib Shows Activity in Advanced/Metastatic RCC

Share this content:

(ChemotherapyAdvisor) – The potent and selective VEGFR-1, -2, -3 inhibitor tivozanib (AV-951) is active and well-tolerated in patients with advanced and metastatic renal cell carcinoma (RCC), according to Phase 2 study results in the Journal of Clinical Oncology online on April 9.

Of 272 patients enrolled in the study, 83% had clear-cell histology, 73% had undergone nephrectomy, and 54% were treatment-naïve. Patients were randomized to receive oral tivozanib 1.5mg/day for three weeks followed by one week off for 16 weeks. Thereafter, the 78 patients who demonstrated ≥25% tumor shrinkage continued to take tivozanib, the 118 patients with <25% tumor change were randomly assigned to tivozanib or placebo, and those with ≥25% tumor growth were discontinued.

Following 16 weeks of treatment with tivozanib, the objective response rate (ORR) was 18%. Significantly more of the 118 patients who received tivozanib remained progression free after 12 weeks compared with those who received placebo (49% vs. 21%; P<0.001.) In the overall study population, ORR was 24% and median progression-free survival was 11.7 months.

Hypertension (12%) was the most common grade 3-4 treatment-related adverse event.

The investigators concluded that these results “support the ongoing Phase 3 evaluation of tivozanib in patients with advanced or metastatic clear-cell RCC.”


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs